PremiumCompany AnnouncementsAnnovis Bio Faces NYSE Non-Compliance Notice Annovis Bio reports Q4 EPS (43c) vs. ($2.24) last year Annovis Bio downgraded to Hold from Buy at D. Boral Capital PremiumThe FlyAnnovis Bio falls -25.6% Annovis Bio announces pricing of $21M offering of stock, warrants Annovis Bio granted U.S. patent covering buntanetap PremiumThe FlyAnnovis Bio reports Q3 EPS (97c), consensus (39c) Annovis Bio appoints Peterson as Senior Clinical Scientist Apple downgraded, Tesla upgraded: Wall Street’s top analyst calls 
